PU-AD (icapamespib), which also targets HSP90-containing epichaperomes [11,71], moved to Phase 2 clinical trials for Alzheimer’s disease and Phase 1 trials for glioblastoma [72]. Here, HSP90AA1 is linked to Alzheimer disease.